

## **Antinociceptive and Analgesic Effects of (2*R*,6*R*)-hydroxynorketamine**

Jonathan G. Yost<sup>1</sup>, Hildegard A. Wulf<sup>2</sup>, Caroline A. Browne<sup>1,2</sup>, Irwin Lucki<sup>1,2,3</sup>

<sup>1</sup>Neuroscience Graduate Program, Uniformed Services University, Bethesda, MD 20814

<sup>2</sup>Department of Pharmacology and Molecular Therapeutics, Uniformed Services University, Bethesda, MD 20814

<sup>3</sup>Department of Psychiatry, Uniformed Services University, Bethesda, MD 20814

## Running Title Page

a) Running title: (2*R*,6*R*)-HNK antinociception and analgesia

b) Corresponding Author:  
Irwin Lucki  
Department of Pharmacology & Molecular Therapeutics  
Uniformed Services University  
3401 Jones Bridge Road  
Bethesda, MD 20814  
[irwin.lucki@usuhs.edu](mailto:irwin.lucki@usuhs.edu)

c) Text pages: 22  
Figures: 4  
Tables: 1  
References: 48  
Words in Abstract: 249  
Words in Introduction: 646  
Words in Discussion: 1,491

d) Abbreviations:  
(2*R*,6*R*)-HNK: (2*R*,6*R*)-hydroxynorketamine  
HNK: hydroxynorketamine  
AMPA:  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors  
NBQX: 2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline

e) Recommended section: Drug Discovery and Translational Medicine

**Keywords:** pain; analgesia; antinociception; (2*R*,6*R*)-HNK; (2*R*,6*R*)-hydroxynorketamine;  
ketamine; ketamine metabolites; glutamate; novel pain therapeutic; non-opioid pain therapeutic.

## Abstract

Commonly utilized pain therapeutics like opioid medications exert dangerous side effects and lack effectiveness in treating some types of pain. Ketamine is also used to treat pain, but side effects limit its widespread use. (2*R*,6*R*)-hydroxynorketamine (HNK) is a ketamine metabolite that potentially shares some beneficial behavioral effects of its parent drug without causing significant side effects. This study compared the profile and potential mechanisms mediating the antinociception activity of ketamine and (2*R*,6*R*)-HNK in C57BL/6J mice. Additionally, this study compared the reversal of mechanical allodynia by (2*R*,6*R*)-HNK with gabapentin in a model of neuropathic pain. Unlike the near-immediate and short-lived antinociception caused by ketamine, (2*R*,6*R*)-HNK produced late-developing antinociception 24 hours following administration. Pharmacological blockade of AMPA receptors with NBQX prevented the initiation and expression of (2*R*,6*R*)-HNK antinociception, suggesting the involvement of AMPA receptor-dependent glutamatergic mechanisms in the pain reduction-like responses. Blockade of opioid receptors with naltrexone partially prevented the antinociceptive effect of ketamine but was ineffective against (2*R*,6*R*)-HNK. Furthermore, (2*R*,6*R*)-HNK did not produce dystaxia, even when tested at doses five times greater than those needed to produce antinociception, indicating a superior safety profile for (2*R*,6*R*)-HNK over ketamine. Additionally, (2*R*,6*R*)-HNK reversed mechanical allodynia in an SNI model of neuropathic pain with similar short-term efficacy to gabapentin (within 4 hours) while outperforming gabapentin 24 hours after administration. These findings support the further study of (2*R*,6*R*)-HNK as a potentially valuable agent for treating different types of pain and establish certain advantages of (2*R*,6*R*)-HNK treatment over ketamine and gabapentin in corresponding assays for pain.

**SIGNIFICANCE STATEMENT:** The ketamine metabolite (2*R*,6*R*)-HNK produced antinociception in male and female mice 24 hours after administration via activation of AMPA receptors. The effects of (2*R*,6*R*)-HNK differed in time course and mechanism and presented a

better safety profile than ketamine. (2*R*,6*R*)-HNK also reversed allodynia in SNI-operated animals within 4 hours of treatment onset, with a duration of effect lasting longer than gabapentin. Taken together, (2*R*,6*R*)-HNK demonstrates the potential for development as a non-opioid analgesic drug.

## Introduction

An estimated 20.4% of adults in the U.S. suffer from a pain condition. For many adults, pain is sufficient to cause significant limitations in their work capability, social life, or ability to provide self-care (Dahlhamer et al., 2018). Inadequately treating pain over time increases the risk of developing psychological disorders such as depression (Fine, 2011). Finding effective pain treatments has proven difficult for many suffering from pain conditions. Ketamine is an anesthetic medication in use since 1970 and known to effectively treat both acute pain (Schwenk et al., 2018) and pain conditions that are chronic and difficult to treat (Eide et al., 1994; Kvarnström et al., 2003; Sigtermans et al., 2009; Cohen et al., 2018). However, clinical treatment of pain with ketamine or its use by patients at home is limited because the drug causes a hallucinogenic state of dissociation, induces behavioral impairment through sedation, and is diverted for recreational abuse. Ketamine is not approved for treating pain by the Food and Drug Administration.

More recently, ketamine has demonstrated effectiveness in providing rapid onset and prolonged relief from treatment-resistant depression (Berman et al., 2000; Ibrahim et al., 2011; Zarate et al., 2012). Based on a compelling body of evidence, the FDA approved the use of the S enantiomer (esketamine) for the indication of treatment-resistant depression in 2019. This breakthrough in depression treatment helped drive a new investigation of ketamine metabolites. Available preclinical data suggest one of the ketamine metabolites, (2R,6R)-hydroxynorketamine (HNK), may share ketamine's therapeutic effects in rodent models of stress exposure (Zanos et al., 2016; Chou et al., 2018) while lacking the liabilities for abuse potential and dissociative cognition seen with the parent drug (Zanos et al., 2016; Pham et al., 2018; Lumsden et al., 2019).

Given ketamine's efficacy in treating pain conditions, it was natural to question whether (2R,6R)-HNK shares analgesic properties with the parent compound. A study recently

demonstrated that a single (2*R*,6*R*)-HNK dose (10 mg/kg) produced a reversal of allodynia in models of postoperative pain, neuropathic pain, and Chronic Regional Pain Syndrome type pain for up to 24 hours following treatment in mice (Kroin et al., 2019). These studies supported the supposition that (2*R*,6*R*)-HNK could be a putative analgesic agent. Still, the time course of treatment onset, ideal doses to treat acute and chronic pain conditions, mechanism of action, and the impact of sex on these outcomes are unknown. Moreover, the antinociceptive effects of (2*R*,6*R*)-HNK have not been examined in animals with no existing pain condition. To replicate the initial findings and provide more information on the antinociceptive effects of (2*R*,6*R*)-HNK, a series of studies were conducted in healthy mice to determine if (2*R*,6*R*)-HNK produces antinociception, to identify the optimal dose and temporal pattern for (2*R*,6*R*)-HNK mediated pain reduction, to evaluate sex differences, and to compare the side effect profile and mechanism of action between (2*R*,6*R*)-HNK and ketamine. Mechanism of action experiments targeted AMPA and opioid receptors due to the identified association between (2*R*,6*R*)-HNK and increases in AMPA receptor (AMPA) dependent glutamatergic signaling and receptor expression (Zanos et al., 2016; Pham et al., 2018) as well as the implication of opioid receptor dependency for some of ketamine's therapeutic effects. The effects of (2*R*,6*R*)-HNK were then examined in the SNI model of neuropathic pain, comparing the time course for reversing allodynia by two doses of (2*R*,6*R*)-HNK with two doses of the common neuropathic pain treatment gabapentin.

The results showed that (2*R*,6*R*)-HNK produced delayed antinociception lasting more than 24 hours in male and female mice. Unlike ketamine, (2*R*,6*R*)-HNK antinociception did not involve opioid receptor activation but was initiated and sustained by the activation of AMPAR. Additionally, (2*R*,6*R*)-HNK reversed mechanical allodynia in SNI-treated mice with a similar short-term onset but lasted longer than gabapentin. Finally, (2*R*,6*R*)-HNK did not produce the dystaxic effects associated with ketamine treatment. These findings support the further development of (2*R*,6*R*)-HNK as a potential analgesic agent for treating different types of pain.

## Materials and Methods

### Animals

Male and female C57BL/6J mice (Jackson Laboratory; Bar Harbor, ME), age 8-15 weeks, were housed with four to five animals per cage, maintained on a standard 12-hour light/dark cycle (lights on at 06:00), and provided with food and water *ad libitum*. Each experiment was conducted with separate cohorts of animals. The animals were randomly assigned to treatment groups for all experiments. Measurements from mice were excluded from experiments if their baseline response extended beyond mean group values by two standard deviations. All experiments were carried out following the National Institutes of Health (NIH) guidelines for the care and use of laboratory animals and with approval from the Uniformed Services University of the Health Sciences Institutional Animal Care and Use Committee.

### Drugs

The (2*R*,6*R*)-HNK and (2*S*,6*S*)-HNK used for these experiments were obtained from the National Center for Advancing Translational Sciences (NCATS; Bethesda, MD), which was synthesized as previously described (Morris et al., 2017). (*R/S*) ketamine was purchased from Mylan Pharmaceuticals (Canonsburg, PA; #67457010810), while gabapentin was obtained from Acros Organics through Fisher Scientific (#458020010). The  $\alpha$ -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA) antagonist NBQX disodium salt (2,3-dioxo-6-nitro-7-sulfamoyl-benzo[f]quinoxaline, Tocris, #1044) and the opioid receptor antagonist naltrexone hydrochloride (Millipore Sigma, MO; #N3136) were used in the pharmacological mechanism of action studies. Physiological saline (0.9% NaCl; Quality Biological, MD; #114-055-721) was used as the control and to dilute medications. Doses were calculated according to the molecular

weight of the base. All drugs were administered via the intraperitoneal route at a 10 ml/kg volume.

#### Antinociception in healthy animals.

Antinociception was assessed in normal healthy mice by measuring paw withdrawal latencies on a Thermal Analgesia Meter (Ugo Basile, Stoelting Co.; Wood Dale, IL) set to 50°C, as described previously (Jacobson et al., 2020). After placement on the hot plate, the latency for the mouse to either jump or lick a hind paw was measured. The animal was immediately removed from the hot plate upon response.

The antinociceptive effects of ketamine 10 and 30 mg/kg, (2*R*,6*R*)-HNK 10 mg/kg, and (2*S*,6*S*)-HNK 10 mg/kg with saline control were examined in healthy male mice (N = 10-22, 10 for ketamine 30 mg/kg, 21 for ketamine 10 mg/kg, 20 for saline control, 22 for both HNK groups). Two animals (one from the control group and one from the ketamine 10 mg/kg group) were excluded for baseline values beyond two standard deviations from the group mean. The beneficial effect of (2*R*,6*R*)-HNK (10 mg/kg) on nociception was confirmed in a second experiment that used both males (N = 30) and females (N = 36). Dose-response curves were generated from latencies of male (N = 10-12 per dose) and female (N = 16-17 per dose) mice tested 24 hours following administration of (2*R*,6*R*)-HNK at quarter log doses beginning with 3 mg/kg ( $10^{0.5}$ ) for male or 6 mg/kg ( $10^{0.75}$ ) for female mice and ending with 100 mg/kg ( $10^2$ ), comparing each dose to saline control. Treatment groups in the male mice consisted of 12 animals for the saline group, 11 animals for the 6 and 18 mg/kg groups, and 10 animals for all other groups. Two female animals, one from the saline group and one from the 18 mg/kg group, were excluded for baseline values that exceeded two standard deviations from the group mean.



To test the contribution of opioid receptors in mediating the initiation of (2*R*,6*R*)-HNK's effect on nociception, the nonselective opioid receptor antagonist naltrexone (1 mg/kg) was administered 30 minutes before (2*R*,6*R*)-HNK treatment (N = 12) and the animals underwent testing 24 hours following treatment. The 1 mg/kg dose was selected because it blocked the antinociceptive effects of morphine in the hot plate test (data not shown). To test the contribution of opioid receptors in mediating the expression of (2*R*,6*R*)-HNK's behavioral effects, naltrexone 1 mg/kg was administered 24 hours following (2*R*,6*R*)-HNK treatment (N = 12) and 30 minutes before behavioral testing.

The contribution of AMPAR in the initiation of (2*R*,6*R*)-HNK's delayed antinociception effect was tested by administering the antagonist NBQX 10 mg/kg 30 minutes before (2*R*,6*R*)-HNK treatment (Dalgaard et al., 1994; Karasawa et al., 2005; Zanos et al., 2016) with the animals (N = 12) undergoing testing 24 hours following (2*R*,6*R*)-HNK. Testing for the contribution of AMPAR to the sustained expression of (2*R*,6*R*)-HNK's effect was done by administering NBQX 10 mg/kg 24 hours following (2*R*,6*R*)-HNK (N = 11-12) with hot plate testing 30 minutes later. One animal from the saline/saline group was excluded for a baseline measurement beyond two standard deviations from the group mean. NBQX 10 mg/kg, naltrexone 1 mg/kg, or saline pretreatment 30 minutes before ketamine 10 mg/kg or saline treatment were administered to test the contribution of both opioid and AMPAR in mediating ketamine's antinociception effect (N = 10). In this case, the animals were tested on the hot plate 10 minutes following ketamine or saline treatment.

### Spared nerve injury

**Surgery:** Spared nerve injury (SNI) surgery was performed to model a neuropathic pain condition on male mice aged 8-12 weeks. The model was initially developed in rats (Decosterd and Woolf, 2000) but is also used in mice (Shields et al., 2003; Bourquin et al., 2006). Briefly, mice underwent axotomy of the tibial and peroneal branches of the sciatic nerve while carefully

preserving the sural branch under aseptic conditions and 2-2.5% isoflurane anesthesia. The sciatic nerve branches were gently dissected to minimize stretching of the sural nerve. A 6-0 silk suture was tied tightly around the tibial and peroneal branches just distal to the bifurcation of the sural nerve from the sciatic nerve bundle. A second 6-0 silk suture was tightly applied 1.5 mm distal to the first, and a 1 mm section of the adjoined tibial and peroneal branches was removed. Following surgery, the incision was closed with sutures, and the mice were returned to their home cages after recovery from anesthesia. The total time required for the procedure was 15 minutes or less for each animal. The animals were given 11 days to recover from surgery before further experimentation. All animals exhibited normal food intake, grooming, and regular movements other than favoring the injured limb before post-surgery experimentation.

*Mechanosensitivity (von Frey):* Paw withdrawal threshold (PWT) was measured in SNI treated mice by examining the responses to lateral-plantar stimulation with von Frey aesthesiometer monofilaments (Stoelting Co.; Wood Dale, IL; 58011) using the classic up-down method (Dixon, 1980; Chaplan et al., 1994). The animals were placed in small plastic enclosures atop a wire mesh platform. Monofilaments (beginning with 1.0 g f) were gently applied with sufficient force only to bend the filament slightly. The monofilament was removed after one second of application. A positive response was defined as licking or rapid paw withdrawal upon stimulation. The subsequent monofilament applied was either the next higher or lower force dependent upon the previous response. The animals were given 3-4 minutes between each application. Once a change in response from the previous monofilament applications was recorded, four additional monofilaments were applied, moving up or down according to the prior response. The paw withdrawal threshold (PWT) was defined as the 50% threshold in grams force according to the following formula:  $50\% \text{ threshold (g f)} = \frac{10^{(X_f + k\delta)}}{10,000}$  where  $X_f$  was the value in log units of the final monofilament used,  $k$  was the tabular value for the

response pattern (see Appendix 1 in Chaplan et al., 1994), and  $\delta$  was the average log unit increment between monofilaments (0.224).

The mechanical allodynia reversing effects of (2*R*,6*R*)-HNK (10 and 30 mg/kg) and gabapentin (10 and 30 mg/kg) were compared to saline injection in the SNI operated male mice (N = 9-10, 9 for the saline and gabapentin 30 mg/kg groups and 10 for all other groups). Gabapentin is a calcium channel blocker commonly used to treat neuropathic type pain in humans. In mice, gabapentin has been shown to suppress inflammatory edema (Dias et al., 2014), reverse pain-depressed burrowing behavior (Shepherd et al., 2018), produce antinociception in healthy animals (Kilic et al., 2012), and reverse SNI-induced allodynia (Shepherd and Mohapatra, 2018) at doses as small as 1 mg/kg and up to 30 mg/kg depending upon the effect. In this study, the SNI mice received once-daily treatment for three days with mechanosensitivity testing immediately preceding treatment on day two and at the same time on day four (24 hours following the third and final treatment, see **Figure 4A**).

### Gait analysis

Gait analysis was used to determine if ketamine or (2*R*,6*R*)-HNK produced motor impairments at the doses effective in the pain assays (N = 12 for each group). Gait analysis was performed utilizing the DigiGait™ treadmill system and Video Imaging Acquisition software (Mouse Specifics Inc.; Framingham, MA) adapted from the original protocol (Wooley et al., 2005) with speed set to 9 cm/s and data represented as fore and hind paw measurements for each animal (Browne et al., 2022). This system analyzes paw placement and measures spatiotemporal gait characteristics. Following 30 minutes of habituation to the testing room and five minutes of familiarization with the treadmill apparatus, the animals were treated with either ketamine (10 mg/kg or 30 mg/kg), (2*R*,6*R*)-HNK (10 mg/kg or 50 mg/kg), or saline. Video sequences of two to five seconds were captured for each animal walking on the treadmill ten minutes after injection. The images were then analyzed using the software. Eight animals were

excluded from the study for refusal to walk on the treadmill, one from the ketamine 10 mg/kg, one from the ketamine 30 mg/kg, two from the (2*R*,6*R*)-HNK cohort saline control, two from the (2*R*,6*R*)-HNK 10 mg/kg, and two from the (2*R*,6*R*)-HNK 50 mg/kg groups.

### Data analysis

The data are expressed as scatter plots showing group means  $\pm$  S.D. A repeated measures two-way ANOVA with Dunnett multiple comparisons was used to determine significant differences between groups comparing ketamine, (2*R*,6*R*)-HNK, (2*S*,6*S*)-HNK, and vehicle control thermal pain sensitivity over time. A repeated measures two-way ANOVA with Šidák multiple comparisons was used to compare (2*R*,6*R*)-HNK against saline control in the time course thermal antinociception experiments for male and female animals. In contrast, a repeated measures three-way ANOVA with Tukey multiple comparisons was used to analyze a sex effect in the combined data.

A one-way ANOVA with Dunnett multiple comparisons was used to compare thermal nociception responses to different doses of (2*R*,6*R*)-HNK 24 hours following treatment. Mechanism of action data were analyzed using a two-way ANOVA with Tukey multiple comparisons. Gait characteristics of groups following ketamine or (2*R*,6*R*)-HNK were compared to the respective saline control group using a one-way ANOVA. Repeated measures two-way ANOVA with Tukey multiple comparisons was used to compare two doses of (2*R*,6*R*)-HNK, two doses of gabapentin, and saline control in reversing mechanical allodynia in SNI operated mice. All statistical analyses were performed using GraphPad Prism 9.0.0 for Windows (GraphPad Software; San Diego, CA, [www.graphpad.com](http://www.graphpad.com)). Statistical significance was defined as  $P < 0.05$ .

## Results

### **(2*R*,6*R*)-HNK produced antinociception: time course, sex differences and dose-response curve**

The time course for the effects of ketamine, (2*R*,6*R*)-HNK, and (2*S*,6*S*)-HNK on the hot plate showed different patterns of antinociceptive response (**Figure 1**; time x treatment interaction  $F(20, 450) = 10.60$ ,  $P < 0.0001$ ). The groups were analyzed together and shown in separated graphs for clarity, with the same saline groups shown in both. Mice that received (2*R*,6*R*)-HNK at 10 mg/kg demonstrated increased latency to respond to the heat stimulus 24 hours following injection compared to saline (**Figure 1B**,  $P = 0.0087$ ). Ketamine produced short-lived antinociception with response latencies increasing significantly only at 10 minutes (**Figure 1A**,  $P = 0.0003$  for 10 mg/kg and  $P = 0.0008$  for 30 mg/kg). In contrast, (2*S*,6*S*)-HNK did not increase the response latency at any time point (**Figure 1B**). The same data are shown as %MPE in Supplementary Figure 1.

An additional experiment compared the time course for (2*R*,6*R*)-HNK in male and female mice. The results of this experiment confirmed that (2*R*,6*R*)-HNK increased latency to respond for both male (**Figure 2A**;  $P = 0.0149$ ) and female (**Figure 2B**;  $P = 0.0203$ ) mice 24 hours following treatment when compared to saline control (males: time x treatment interaction  $F(4, 232) = 4.28$ ,  $P = 0.0023$ ; females: time x treatment interaction  $F(4, 280) = 3.884$ ,  $P = 0.0044$ ). The results of the time-course experiment indicate the onset of (2*R*,6*R*)-HNK's delayed antinociception to be between 10- and 24-hours following administration. A three-way ANOVA

of the male and female data, excluding the baseline measurement, revealed a sex effect ( $F(1, 62) = 5.216$ ,  $P = 0.0258$ ). However, the post-hoc analysis revealed no significant sex differences at the same treatment and time. The same data are shown as %MPE in Supplementary Figure 1.

The response on the hot plate was evaluated at quarter log scale doses of (2*R*,6*R*)-HNK 24 hours after administration and revealed an inverted U-shaped dose response curve for both males (**Figure 2C**;  $F(7, 76) = 4.986$ ,  $P = 0.0001$ ) and females (**Figure 2D**;  $F(6, 110) = 4.971$ ,  $P = 0.0002$ ). Specifically, males exhibited increased latencies to doses of 10 mg/kg ( $P = 0.0004$ ) and 18 mg/kg ( $P = 0.0010$ ). Females displayed increases in latency to (2*R*,6*R*)-HNK at doses of 10 mg/kg ( $P = 0.0028$ ), 18 mg/kg ( $P = 0.0262$ ) and 32 mg/kg ( $P = 0.0049$ ). (2*R*,6*R*)-HNK at a dose of 30 mg/kg was also tested at 10 minutes, 1, and 4 hours (data not shown) but did not increase latency to respond to the hotplate at any measured time. Additional examination is required to determine if even higher doses of (2*R*,6*R*)-HNK can reduce the onset of its antinociception effect.

### **AMPA but not opioid receptors are involved in the initiation and expression of the antinociceptive effects of (2*R*,6*R*)-HNK**

The effect of AMPAR blockade on the initiation of (2*R*,6*R*)-HNK antinociception was tested by administering NBQX 30 minutes before injection. Pretreatment with NBQX (10 mg/kg) blocked the (2*R*,6*R*)-HNK generated hot plate effect when tested 24 hours post-injection (**Figure 3A**; pretreatment x treatment interaction,  $F(1, 58) = 4.592$ ,  $P = 0.0363$ , saline/saline vs. saline/HNK  $P = 0.0015$ , saline/HNK vs. NBQX/HNK  $P = 0.0491$ ). The effect of AMPAR blockade on the expression of (2*R*,6*R*)-HNK antinociception was tested by administering NBQX 24 hours following treatment and 30 minutes before testing. NBQX given at this time also blocked the (2*R*,6*R*)-HNK mediated increase in latency to respond to the hot plate (**Figure 3C**; treatment x post-treatment interaction,  $F(1, 43) = 4.972$ ,  $P = 0.0310$ , saline/saline vs. HNK/saline  $P =$

0.0077, HNK/saline vs. HNK/NBQX  $P = 0.0496$ ). Altogether, these data suggest both the initiation and expression of the delayed antinociception effect of (2*R*,6*R*)-HNK is dependent on the interaction between (2*R*,6*R*)-HNK and AMPAR.

The nonselective opioid receptor antagonist naltrexone (1 mg/kg) was used to test the involvement of opioid receptors in the initiation and expression of (2*R*,6*R*)-HNK (10 mg/kg) antinociception. Administration of the naltrexone 30 minutes before (2*R*,6*R*)-HNK treatment had no impact on the initiation of antinociception produced by (2*R*,6*R*)-HNK when measured 24 hours after treatment (**Figure 3B**; HNK/saline treatment effect  $F(1, 44) = 9.364$ ,  $P = 0.0038$ , pretreatment x treatment interaction  $F(1, 44) = 0.01805$ ,  $P = 0.8937$ ). Similarly, the administration of naltrexone 24 hours after (2*R*,6*R*)-HNK treatment and 30 minutes before hot plate testing failed to alter the expression of (2*R*,6*R*)-HNK antinociception (**Figure 3D**; HNK treatment effect,  $F(1, 44) = 13.93$ ,  $P = 0.0005$ , HNK treatment x naltrexone administration interaction  $F(1, 44) = 0.9235$ ,  $P = 0.3418$ ). These data suggest that any potential interaction (2*R*,6*R*)-HNK may have with opioid receptors had no impact on its mediation of antinociception at the initiation of the delayed effect or its expression 24 hours later.

Pretreatment with either saline, NBQX, or naltrexone 30 minutes before ketamine injection was used to test the involvement of AMPA and opioid receptors in the antinociceptive effect of ketamine (10 mg/kg) (**Figure 3E**; pretreatment x ketamine treatment interaction,  $F(2, 54) = 4.634$ ,  $P = 0.0139$ ). AMPAR antagonism with NBQX had no impact on ketamine-mediated antinociception ( $P = 0.9763$ ). In contrast, naltrexone pretreatment reversed ketamine mediated antinociception (saline/ketamine vs naltrexone/ketamine  $P = 0.0072$ ). These results suggests that the mechanism for ketamine's antinociception differs from that of (2*R*,6*R*)-HNK.

**(2*R*,6*R*)-HNK reversed mechanical allodynia in SNI treated mice with a longer duration of effect than gabapentin**

Two doses of (2*R*,6*R*)-HNK (10 and 30 mg/kg) were compared with two doses of gabapentin (10 and 30 mg/kg) for reversal of mechanical allodynia in an SNI model of neuropathic pain. All of the animals exhibited a significantly lower threshold to respond to mechanical stimulation on day 11 after SNI surgery compared to their corresponding baseline values (data not shown, average baseline before surgery for all groups was  $4.3 \pm 1.10$  g f), indicating the presence of mechanical allodynia. There was no significant difference between groups at time 0 (day 11) before treatment. The mice were treated once daily for three days. Mechanosensitivity testing was repeated 4 and 24 hours following the first treatment and again 24 hours following the third treatment (**Figure 4A**). Analysis of the results revealed a time x treatment interaction ( $F(12, 129) = 6.211$ ,  $P < 0.0001$ ). (2*R*,6*R*)-HNK reversed hypersensitivity associated with the SNI condition 4 hours after administration (**Figure 4B**,  $P = 0.0003$  for 10 mg/kg and  $P < 0.0001$  for 30 mg/kg). (2*R*,6*R*)-HNK's allodynia-reversing effect persisted for greater than 24 hours after a single dose ( $P < 0.0001$  for 10 mg/kg and  $P < 0.0001$  for 30 mg/kg) and was still present 24 hours following the third treatment ( $P = 0.0023$  for 10 mg/kg and  $P < 0.0001$  for 30 mg/kg). Both doses of gabapentin reversed the hypersensitivity when tested 4 hours after treatment ( $P = 0.0005$  for 10 mg/kg and  $P < 0.0001$  for 30 mg/kg). However, gabapentin failed to maintain a reversal of mechanical allodynia 24 hours following the first or even third drug treatment.

### **(2*R*,6*R*)-HNK did not impair gait or induce loss of motor coordination, unlike ketamine**

Male mice underwent gait analysis 10 minutes following treatment with either ketamine at doses of 10 mg/kg and 30 mg/kg or (2*R*,6*R*)-HNK at doses of 10 mg/kg and 50 mg/kg. The animals' gait characteristics were compared to animals that received saline injections. Animals receiving ketamine exhibited dose-dependent alterations in fore and hind paw gait parameters, including brake/stride ratio, propel/stride ratio, paw area variability at peak stance, propel duration, and brake duration (**Table 1**). These gait alterations, taken altogether, reflect a



reduction in motor coordination. In contrast, animals receiving (2*R*,6*R*)-HNK did not exhibit significant changes in any of these parameters even at 50 mg/kg, which is five times greater than the dose needed to produce antinociception or analgesia.

## Discussion

In this study, the ketamine metabolite (2*R*,6*R*)-HNK produced an increase in the threshold for healthy mice to respond to a painful heat stimulus (**Figure 1 and 2**) and reversed SNI induced mechanical allodynia (**Figure 4**). Antinociception on the hot plate was produced in healthy animals without a pre-existing pain condition and is a standard screen for analgesic drugs (Piercey and Schroeder, 1981). Ketamine showed some key differences from (2*R*,6*R*)-HNK. Ketamine-mediated antinociception was rapid (onset < 10 minutes) and lasted less than 1 hour. In contrast, (2*R*,6*R*)-HNK produced delayed antinociception measured 24 hours after injection when the drug has already been eliminated from the body (Zanos et al., 2016). Moreover, the pain-reducing effects of ketamine were mediated partially through opioid receptors, while those of (2*R*,6*R*)-HNK were AMPAR dependent and opioid-receptor independent (**Figure 3**). The persistent duration of (2*R*,6*R*)-HNK analgesia was also seen in effects measured with the SNI model. (2*R*,6*R*)-HNK produced an acute and prolonged increase in threshold to respond to mechanical stimulation with a duration of action exceeding that of gabapentin, a drug used to treat neuropathic pain, even after repeated dosing.

An earlier publication demonstrated that (2*R*,6*R*)-HNK could reverse mechanical allodynia associated with acute and chronic pain conditions in mice (Kroin et al., 2019). The reduction in mechanical allodynia was evident as early as within 1 hour, persisted for 24 hours after a single administration, and continued even up to 72 hours after once-daily repeated administration. The onset of the antinociception by (2*R*,6*R*)-HNK described in this study occurred between 10 and 24 hours. Still, it was active beyond the expected physical presence of the drug, considering the half-life of (2*R*,6*R*)-HNK in the brain is approximately 1 hour (Zanos et al., 2016), and plasma half-life is 0.2-0.8 hours in mice (Highland et al., 2019). These data suggest that persistent changes in neuroplasticity, presently unidentified, induced by (2*R*,6*R*)-HNK may underlie the protracted antinociception effect.

(2*S*,6*S*)-HNK is another ketamine metabolite receiving attention for its potential role in ketamine's antidepressant behavioral effects. This metabolite would be derived in racemic form from *RS*-ketamine or selectively from *S*-ketamine, an antidepressant approved by the FDA in the form of a nasal spray (Spravato®). Several studies have found that (2*R*,6*R*)-HNK was more potent and effective than (2*S*,6*S*)-HNK on tests in rodents for antidepressant activity (Zanos et al., 2016; for review, see Highland et al., 2021). However, a recent study demonstrated that (2*S*,6*S*)-HNK, and not (2*R*,6*R*)-HNK, effectively reversed depression-like behavior in a corticosterone-induced mouse model of depression (Yokoyama et al., 2020). In these experiments, (2*S*,6*S*)-HNK at doses of 10 mg/kg (**Figure 1B**) and 30 mg/kg (data not shown) did not produce antinociception. Although additional doses could be tested, (2*S*,6*S*)-HNK did not appear to produce the analgesia-like effects produced by (2*R*,6*R*)-HNK and racemic ketamine.

This study is the first to investigate a dose-response relationship for (2*R*,6*R*)-HNK mediated reduction of pain behavior. The inverted U-shaped dose response for antinociception was consistent between male and female mice. (2*R*,6*R*)-HNK also showed an inverted U-

shaped dose-response to reduce escape failures in an inescapable shock paradigm (Zanos et al., 2019). The loss of antinociception as the (2*R*,6*R*)-HNK dose increased to and above 30 mg/kg in this study does not likely reflect behavioral competition because (2*R*,6*R*)-HNK does not alter motor coordination or locomotor activity (Zanos et al., 2016). Instead, the descending limb may reflect competing downstream effects of (2*R*,6*R*)-HNK at higher doses that are yet unidentified. Interestingly, some of ketamine's behavioral and cellular therapeutic effects have also shown an inverted U-shaped dose response. Ketamine induced mTOR activation in the rat prefrontal cortex at moderate doses, while low or high doses produced no effect (Li et al., 2010).

The mechanism underlying the initiation of delayed antinociception of (2*R*,6*R*)-HNK was investigated using antagonists for AMPA and opioid receptors. (2*R*,6*R*)-HNK has been reported to increase AMPAR dependent synaptic transmission by increasing glutamate release and AMPAR expression (Zanos et al., 2016; Pham et al., 2018). AMPAR antagonism with NBQX has been shown to prevent the sustained antidepressant-like effects in mice by ketamine and (2*R*,6*R*)-HNK 24 hours after injection (Koike and Chaki, 2014; Zanos et al., 2016), demonstrating that some persistent behavioral effects of these drugs appear to be mediated by the AMPAR. AMPAR glutamatergic signaling also is known to play a vital role in pain transmission. Correlations have been identified between increased AMPAR subunit composition within the anterior cingulate cortex and the facilitation of pain signal transmission (Xu et al., 2008) as well as AMPAR subunit expression in the spinal cord and a stress-induced transition from acute to chronic pain (Li et al., 2014). AMPARs have also been implicated in pain-reduction in rodents, where AMPAR positive allosteric modulators (AMPAkines) reduced mechanical allodynia in rats with induced neuropathic and inflammatory type pains (Le et al., 2014). The ability of NBQX to block the behavioral expression of (2*R*,6*R*)-HNK antinociception 24 hours after injection is consistent with (2*R*,6*R*)-HNK producing a persistent increase in AMPAR signal transmission (Zanos et al., 2016; Pham et al., 2018). The results of this study

suggest that (2*R*,6*R*)-HNK induced antinociception requires AMPA receptor activation in both the initiation and expression of the delayed antinociceptive effect. This aligns with previous data where AMPAR blockade inhibited (2*R*,6*R*)-HNK mediated behavioral effects in rodent models of stress and increased gamma power measured via quantitative electroencephalography (Zanos et al., 2016).

The involvement of opioid receptors has also been implicated in ketamine's antidepressant effects. Pretreatment with the nonselective opioid receptor antagonist naltrexone blocked improvements in depression scores associated with ketamine infusion therapy in humans (Williams et al., 2018), signifying the acute antidepressant effects of ketamine are at least partially dependent upon opioid receptor activation. Opioid receptor antagonism has also been shown to block the antinociceptive effects of ketamine on the tail-flick test in mice (Pacheco et al., 2014). In this study, ketamine antinociception was also blocked by naltrexone pretreatment but not AMPAR antagonism. In contrast, (2*R*,6*R*)-HNK antinociception was not blocked by naltrexone pretreatment while AMPAR antagonism blocked the antinociception, signifying that the drugs use different mechanisms to induce pain reduction effects. These results align with previous data where naltrexone did not block (2*R*,6*R*)-HNK mediated reversal of mechanical allodynia in a model of postoperative pain (Kroin et al., 2019).

Kroin et al. (2019) demonstrated that (2*R*,6*R*)-HNK 10 mg/kg reversed mechanical allodynia associated with a model of neuropathic pain in female mice. (2*R*,6*R*)-HNK's allodynia-reversing effect was confirmed in male SNI treated mice using multiple doses and compared the results to gabapentin treatment (**Figure 4**). Acutely, (2*R*,6*R*)-HNK reversed the allodynia 4 hours after administration at 10 and 30 mg/kg. The onset of analgesia for (2*R*,6*R*)-HNK in the SNI model was more rapid than the antinociceptive effects in healthy animals and may reflect changes in behavioral sensitivity when testing in the presence of spontaneous pain. Nevertheless, (2*R*,6*R*)-HNK demonstrated a sustained analgesic effect 24 hours after

treatment, whereas gabapentin did not. Although similar to gabapentin when tested at 4 hours, the effects of (2*R*,6*R*)-HNK persisted longer than gabapentin following cessation of a once-daily for three days dosing regimen, indicating that (2*R*,6*R*)-HNK exerts a longer duration of effect compared to gabapentin and is not subject to tolerance under these conditions. Additional research is needed to examine whether (2*R*,6*R*)-HNK's allodynia reversing effect in this model of neuropathic pain, or other pain models, is dependent on AMPAR.

Identifying novel analgesics that lack the side effects common with opioids and ketamine is critical to identifying more effective long-term pain treatments. Ketamine induces transient alterations in motor coordination (Irifune et al., 1995; Razoux et al., 2007), produces dissociative cognition, and demonstrates considerable abuse potential. Careful assessment of motor impairment can differentiate between actual analgesia behavior and analgesia masked by motor dysfunction. Here treatment-induced motor impairment following ketamine or (2*R*,6*R*)-HNK administration was evaluated by analyzing a sensitive computerized assay of gait characteristics. Treadmill videography has been used preclinically to measure spatiotemporal gait alterations resulting from pathological conditions (Berryman et al., 2009; Zhan et al., 2019; Kwok et al., 2020) and may be sensitive enough to identify gait alterations even before the impairment becomes clinically significant. Subsequent analysis identified ketamine-induced dystaxia in several gait parameters (**Table 1**). (2*R*,6*R*)-HNK did not produce changes in gait, even at doses considerably higher than required to achieve a pain reduction-like effect. Based on the present and published data, (2*R*,6*R*)-HNK is unlikely to induce motor incoordination, impair sensorimotor gaiting, or possess rewarding effects (Zanos et al., 2016; Lilius et al., 2018).

In conclusion, these data indicate that (2*R*,6*R*)-HNK can produce antinociception and analgesia in animals, with a duration of action that exceeds its physical presence. (2*R*,6*R*)-HNK likely initiates and sustains this effect through persistent activation of AMPAR, a different

mechanism than other common pain therapeutics. In addition, (2*R*,6*R*)-HNK does not produce the side effects that limit the clinical utility of other strong analgesic medications. Further investigation into the mechanism underlying (2*R*,6*R*)-HNK's antinociceptive effects and exploration of its efficacy in different pain conditions may prove valuable towards developing novel therapeutics for treating pain conditions and discerning pathophysiological alterations that may be normalized by (2*R*,6*R*)-HNK treatment in spontaneous pain conditions.

## Acknowledgments

The authors thank Dr. Mumeko C. Tsuda and Ms. Laura Tucker for their assistance with the assays used in this research and the resources made available to us through the Preclinical Behavior and Modeling Core at Uniformed Services University of the Health Sciences. We appreciate Dr. Yumin Zhang's help with training in developing the SNI pain model. We are grateful to Dr. Craig J. Thomas and Dr. Patrick Morris of the National Center for Advancing Translational Sciences for help in obtaining (2R,6R)-hydroxynorketamine and for helpful comments on this manuscript. The information or content and conclusions do not necessarily represent the official position or policy of, nor should any official endorsement be inferred by, the TriService Nursing Research Program, the Uniformed Services University of the Health Sciences, the Department of Defense, or the U.S. Government.

## Authorship Contributions

*Participated in research design:* Yost, Browne, Lucki

*Conducted experiments:* Yost, Wulf, Browne

*Performed data analysis:* Yost, Wulf, Browne, Lucki

*Wrote or contributed to the writing of the manuscript:* Yost, Browne, Lucki

## References

- Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS and Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. *Biological psychiatry* **47**:351-354.
- Berryman ER, Harris RL, Moalli M and Bagi CM (2009) Digigait quantitation of gait dynamics in rat rheumatoid arthritis model. *Journal of musculoskeletal & neuronal interactions* **9**:89.
- Bourquin A-F, Süveges M, Pertin M, Gilliard N, Sardy S, Davison AC, Spahn DR and Decosterd I (2006) Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mouse. *Pain* **122**:14. e11-14. e14.
- Browne CA, Wulf HA, Jacobson ML, Oyola MG, Wu TJ and Lucki I (2022) Long-term increase in sensitivity to ketamine's behavioral effects in mice exposed to mild blast induced traumatic brain injury. *Experimental neurology* **350**:113963-113963.
- Chaplan SR, Bach FW, Pogrel JW, Chung JM and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. *Journal of Neuroscience Methods* **53**:55-63.
- Chou D, Peng HY, Lin TB, Lai CY, Hsieh MC, Wen YC, Lee AS, Wang HH, Yang PS, Chen GD and Ho YC (2018) (2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. *Neuropharmacology* **139**:1-12.
- Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, Viscusi ER, Narouze S, Davis FN, Ritchie EC, Lubenow TR and Hooten WM (2018) Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. *Regional Anesthesia and Pain Medicine* **43**:521-546.
- da Fonseca Pacheco D, Romero TRL and Duarte IDG (2014) Central antinociception induced by ketamine is mediated by endogenous opioids and  $\mu$ - and  $\delta$ -opioid receptors. *Brain research* **1562**:69-75.
- Dahlhamer J, Lucas J, Zelaya C, Nahin R, Mackey S, DeBar L, Kerns R, Von Korff M, Porter L and Helmick C (2018) Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. *MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT* **67**:1001-1006.
- Dalgaard L, Hjortkjaer RK, Regnier B and Nordholm L (1994) Pharmacokinetics of the neuroprotective glutamate antagonist NBQX (6-nitro-7-sulfamoyl-benzo (f) quinoxaline-2, 3-dione) in mice, rats, and dogs. Interactions with probenecid. *Drug metabolism and disposition* **22**:289-293.
- Decosterd I and Woolf CJ (2000) Spared nerve injury: an animal model of persistent peripheral neuropathic pain. *Pain* **87**:149-158.



- Dias JM, de Brito TV, de Aguiar Magalhães D, da Silva Santos PW, Batista JA, do Nascimento Dias EG, de Barros Fernandes H, Damasceno SRB, Silva RO and Aragão KS (2014) Gabapentin, a synthetic analogue of gamma aminobutyric acid, reverses systemic acute inflammation and oxidative stress in mice. *Inflammation* **37**:1826-1836.
- Dixon WJ (1980) Efficient analysis of experimental observations. *Annual review of pharmacology and toxicology* **20**:441-462.
- Eide PK, Jørum E, Stubhaug A, Bremnes J and Breivik H (1994) Relief of post-herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross-over comparison with morphine and placebo. *Pain* **58**:347-354.
- Fine PG (2011) Long-Term Consequences of Chronic Pain: Mounting Evidence for Pain as a Neurological Disease and Parallels with Other Chronic Disease States. *Pain medicine (Malden, Mass)* **12**:996-1004.
- Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA, Thomas CJ, Moaddel R and Gould TD (2019) Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R, 6R)-hydroxynorketamine. *Journal of Psychopharmacology* **33**:12-24.
- Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG and Zarate CA (2011) Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* **35**:1155-1159.
- Irifune M, Shimizu T, Nomoto M and Fukuda T (1995) Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice. *Pharmacology Biochemistry and Behavior* **51**:291-296.
- Jacobson ML, Wulf HA, Browne CA and Lucki I (2020) The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice. *Psychopharmacology (Berlin, Germany)* **237**:3715-3728.
- Karasawa J-i, Shimazaki T, Kawashima N and Chaki S (2005) AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. *Brain research* **1042**:92-98.
- Kilic FS, Sirmagul B, Yildirim E, Oner S and Erol K (2012) Antinociceptive effects of gabapentin & its mechanism of action in experimental animal studies. *INDIAN JOURNAL OF MEDICAL RESEARCH* **135**:630-635.
- Koike H and Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. *Behavioural brain research* **271**:111-115.
- Kroin JS, Das V, Moric M and Buvanendran A (2019) Efficacy of the ketamine metabolite (2R,6R)-hydroxynorketamine in mice models of pain. *Regional Anesthesia & Pain Medicine* **44**:111-117.

- Kvarnström A, Karlsten R, Quiding H, Emanuelsson BM and Gordh T (2003) The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. *Acta anaesthesiologica scandinavica* **47**:868-877.
- Kwok A, Rosas S, Bateman TA, Livingston E, Smith TL, Moore J, Zawieja DC, Hampton T, Mao XW, Delp MD and Willey JS (2020) Altered rodent gait characteristics after ~35 days in orbit aboard the International Space Station. *Life Sciences in Space Research* **24**:9-17.
- Le AM, Lee M, Su C, Zou A and Wang J (2014) AMPAkinases have novel analgesic properties in rat models of persistent neuropathic and inflammatory pain. *Anesthesiology* **121**:1080-1090.
- Li C, Yang Y, Liu S, Fang H, Zhang Y, Furmanski O, Skinner J, Xing Y, Johns RA and Huganir RL (2014) Stress induces pain transition by potentiation of AMPA receptor phosphorylation. *Journal of Neuroscience* **34**:13737-13746.
- Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, Li X-Y, Aghajanian G and Duman RS (2010) mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists. *Science (American Association for the Advancement of Science)* **329**:959-964.
- Lilius TO, Viisanen H, Jokinen V, Niemi M, Kalso EA and Rauhala PV (2018) Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine. *Basic & Clinical Pharmacology & Toxicology* **122**:481-488.
- Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA, Jr., Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX and Gould TD (2019) Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function. *Proc Natl Acad Sci U S A* **116**:5160-5169.
- Monteggia LM and Zarate C (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. *Current opinion in neurobiology* **30**:139-143.
- Morris PJ, Moaddel R, Zanos P, Moore CE, Gould T, Zarate CA and Thomas CJ (2017) Synthesis and N-Methyl-D-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. *Organic Letters* **19**:4572-4575.
- Pham TH, Defaix C, Xu X, Deng SX, Fabresse N, Alvarez JC, Landry DW, Brachman RA, Denny CA and Gardier AM (2018) Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects. *Biol Psychiatry* **84**:e3-e6.
- Piercey MF and Schroeder LA (1981) Spinal and supraspinal sites for morphine and nefopam analgesia in the mouse. *European journal of pharmacology* **74**:135-140.
- Razoux F, Garcia R and Léna I (2007) Ketamine, at a dose that disrupts motor behavior and latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the nucleus accumbens. *Neuropsychopharmacology* **32**:719-727.

- Schwenk ES, Viscusi ER, Buvanendran A, Hurley RW, Wasan AD, Narouze S, Bhatia A, Davis FN, Hooten WM and Cohen SP (2018) Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Acute Pain Management From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. *Regional Anesthesia and Pain Medicine* **43**:456-466.
- Shepherd AJ, Cloud ME, Cao Y-Q and Mohapatra DP (2018) Deficits in burrowing behaviors are associated with mouse models of neuropathic but not inflammatory pain or migraine. *Frontiers in Behavioral Neuroscience* **12**:124.
- Shepherd AJ and Mohapatra DP (2018) Pharmacological validation of voluntary gait and mechanical sensitivity assays associated with inflammatory and neuropathic pain in mice. *Neuropharmacology* **130**:18-29.
- Shields SD, Eckert WA and Basbaum AI (2003) Spared nerve injury model of neuropathic pain in the mouse: a behavioral and anatomic analysis. *Journal of Pain* **4**:465-470.
- Sigtermans MJ, Van Hilten JJ, Bauer MC, Arbous MS, Marinus J, Sarton EY and Dahan A (2009) Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type 1. *Pain* **145**:304-311.
- Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, Hawkins J, Birnbaum J, Lyons DM and Rodriguez CI (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. *American Journal of Psychiatry* **175**:1205-1215.
- Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA and Seburn KL (2005) Gait analysis detects early changes in transgenic SOD1 (G93A) mice. *Muscle & Nerve: Official Journal of the American Association of Electrodiagnostic Medicine* **32**:43-50.
- Xu H, Wu L-J, Wang H, Zhang X, Vadakkan KI, Kim SS, Steenland HW and Zhuo M (2008) Presynaptic and postsynaptic amplifications of neuropathic pain in the anterior cingulate cortex. *Journal of Neuroscience* **28**:7445-7453.
- Yokoyama R, Higuchi M, Tanabe W, Tsukada S, Naito M, Yamaguchi T, Chen L, Kasai A, Seiriki K and Nakazawa T (2020) (S)-norketamine and (2S, 6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. *Pharmacology Biochemistry and Behavior* **191**:172876.
- Zanos P, Highland JN, Liu X, Troppoli TA, Georgiou P, Lovett J, Morris PJ, Stewart BW, Thomas CJ, Thompson SM, Moaddel R and Gould TD (2019) (R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses. *British Journal of Pharmacology* **176**:2573-2592.
- Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, Alkondon M, Yuan P, Pribut HJ, Singh NS, Dossou KS, Fang Y, Huang XP, Mayo CL, Wainer IW, Albuquerque EX, Thompson SM, Thomas CJ, Zarate CA, Jr. and Gould TD (2016) NMDAR inhibition-independent antidepressant actions of ketamine metabolites. *Nature* **533**:481-486.

- Zarate CA, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V and Luckenbaugh DA (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. *Biological psychiatry* **71**:939-946.
- Zhan J, Yakimov V, Rühling S, Fischbach F, Nikolova E, Joost S, Kaddatz H, Greiner T, Frenz J and Holzmann C (2019) High speed ventral plane videography as a convenient tool to quantify motor deficits during preclinical experimental autoimmune encephalomyelitis. *Cells* **8**:1439.

## Footnotes

This research was sponsored by the TriService Nursing Research Program, Uniformed Services University of the Health Sciences (Grant NA20-A02GR), and CDMRP (Award W81XWH-21-2-011). The information or content and conclusions do not necessarily represent the official position or policy of, nor should any official endorsement be inferred by, the TriService Nursing Research Program, Uniformed Services University of the Health Sciences, the Department of Defense, or the U.S. Government.

No author has an actual or perceived conflict of interest with the contents of this article.

Data from this article were presented in abstracts and podium/poster presentations at:

- Uniformed Services University Research Days Graduate Student Colloquium, May 2020, Bethesda, MD
- Military Health System Research Symposium, Sept 2020, venue canceled (abstract only)
- Uniformed Services University Research Days Graduate Student Colloquium, May 2021, Bethesda, MD
- Military Health System Research Symposium, Sept 2020, venue canceled (abstract only)
- Annual Meeting of the American College of Neuropsychopharmacology, Dec 2021, San Juan, Puerto Rico
- ASPET Annual Meeting at EB22, Apr 2022, Philadelphia, PA

Submit reprint requests through:

Irwin Lucki  
Department of Pharmacology & Molecular Therapeutics  
Uniformed Services University  
3401 Jones Bridge Road  
Bethesda, MD 20814  
[irwin.lucki@usuhs.edu](mailto:irwin.lucki@usuhs.edu)

## Figure Legends

**Figure 1.** (2*R,6R*)-HNK produced delayed antinociception (**Panel B**), while ketamine produced rapid and short-lived antinociception (**Panel A**). (2*S,6S*)-HNK did not produce antinociception at any time point (**Panel B**). The data were analyzed together using a repeated measures two-way ANOVA but are shown in two separate graphs for clarity. The error bars represent group means  $\pm$  S.D. Comparisons are made between drug/dose and saline at the same time point: \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .  $N = 20$  for saline control,  $N = 21$  for ketamine 10 mg/kg,  $N = 10$  for ketamine 30 mg/kg,  $N = 22$  for both HNK groups.

**Figure 2.** Male (**Panel A**) and female (**Panel B**) time course for latency to respond to hot plate stimulus following (2*R,6R*)-HNK 10 mg/kg treatment. Comparisons are made between the treatment and saline groups at the same time point: \*  $P < 0.05$ .  $N = 30$  for males and  $N = 36$  for females. **Panel C** (males) & **Panel D** (females) represent the quarter log dose-response for (2*R,6R*)-HNK mediated antinociception measured 24 hours after treatment. (2*R,6R*)-HNK produced antinociception at doses of 10 and 18 mg/kg in both sexes, while the 32 mg/kg dose produced antinociception in female mice only. Asterisks indicate significant differences compared to the saline control. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .  $N = 10-12$  for males, and  $N = 17$  for females. The error bars represent group means  $\pm$  S.D. For the dose-response figures, the mean of the saline group is represented by the dashed line while the  $\pm$  S.D. are represented by dotted lines.

**Figure 3.** The effects of AMPA receptor antagonism with NBQX (10 mg/kg) or opioid receptor antagonism with naltrexone (1 mg/kg) on the initiation or expression of antinociception by (2*R,6R*)-HNK. The effects of (2*R,6R*)-HNK (10 mg/kg) were measured 24 hours after injection. **Panel A:** The NBQX given 30 minutes before (2*R,6R*)-HNK treatment blocked the initiation of (2*R,6R*)-HNK antinociception. **Panel B:** Naltrexone given 30 minutes before (2*R,6R*)-HNK treatment did not block the initiation of (2*R,6R*)-HNK antinociception. **Panel C:** NBQX given 24


hours following (2*R*,6*R*)-HNK treatment blocked the expression of (2*R*,6*R*)-HNK mediated antinociception. **Panel D:** Naltrexone given 24 hours following (2*R*,6*R*)-HNK treatment did not alter (2*R*,6*R*)-HNK antinociception. **Panel E:** Ketamine (10 mg/kg) mediated antinociception measured 10 minutes following treatment was unaffected by pretreatment with NBQX (10 mg/kg given 30 minutes prior) while naltrexone (1 mg/kg given 30 minutes prior) blocked ketamine antinociception. The error bars represent group means  $\pm$  S.D. Group comparisons are indicated with horizontal lines. Asterisks represent treatment/saline to saline/saline comparisons: \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , and \*\*\*\*  $P < 0.0001$ . The # symbol represents treatment/NBQX to treatment/saline comparisons: #  $P < 0.05$ , ##  $P < 0.01$ , and ###  $P < 0.001$ . The @ symbol represents NBQX/saline compared with NBQX/ketamine: @@@@,  $P < 0.0001$ .  $N = 11-12$  for the (2*R*,6*R*)-HNK experiments,  $N = 10$  for the ketamine experiment.

**Figure 4.** The SNI condition produced mechanical allodynia 11 days after surgery. Time 0 represents mechanosensitivity results on day 11 before treatment. Results of a baseline measurement before surgery demonstrated no significant difference between groups (data not shown, average baseline before surgery for all groups was  $4.3 \pm 1.10$  g f). **Panel A:** The experimental paradigm comprised once-daily treatment for three days and mechanosensitivity testing before daily treatment. **Panel B:** (2*R*,6*R*)-HNK reversed mechanical allodynia associated with the neuropathic pain condition within 4 hours of treatment, and the effect persisted for at least 24 hours. Repeat dosing did not appear to lessen the pain reduction-like effect. Gabapentin reversed mechanical allodynia 4 hours following treatment but did not produce a significant effect 24 hours following the first or third treatment. Vertical bars represent the group means  $\pm$  S.D. Drug doses are compared to saline at the same time point, \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , \*\*\*\*  $P < 0.0001$ ,  $N = 9-10$  ( $N = 9$  for saline and gabapentin 30 mg/kg groups,  $N = 10$  for all other groups).

Parameter	Treatment		Saline	10 mg/kg (for Ket) 10 mg/kg (for HNK)	30 mg/kg (for Ket) 50 mg/kg (for HNK)	Treatment effect
Brake/Stride Ratio (%)	Ketamine	Forepaw	26.15 ± 7.35	29.06 ± 6.52	34.89 ± 9.27	F(2, 65) = 7.433, P = 0.0012
		Hindpaw	13.35 ± 5.41	17.81 ± 6.56	19.69 ± 7.43	F(2, 65) = 5.849, P = 0.0046
	(2R,6R)-HNK	Forepaw	33.44 ± 6.91	32.92 ± 6.17	30.36 ± 7.68	n.s.
		Hindpaw	15.36 ± 6.35	16.50 ± 7.59	16.29 ± 5.99	n.s.
Propel/Stride Ratio (%)	Ketamine	Forepaw	43.55 ± 7.13	39.62 ± 7.16	37.09 ± 9.91	F(2, 65) = 3.689, P = 0.0304
		Hindpaw	62.92 ± 7.32	60.46 ± 6.61	55.47 ± 8.83	F(2, 65) = 5.612, P = 0.0056
	(2R,6R)-HNK	Forepaw	37.88 ± 5.65	36.41 ± 6.36	38.89 ± 5.87	n.s.
		Hindpaw	62.00 ± 7.98	60.99 ± 8.42	61.59 ± 6.95	n.s.
Paw Area Variability at Peak Stance (cm <sup>2</sup> )	Ketamine	Forepaw	0.026 ± 0.008	0.036 ± 0.017	0.048 ± 0.022	F(2, 65) = 9.973, P = 0.0002
		Hindpaw	0.054 ± 0.026	0.057 ± 0.025	0.095 ± 0.045	F(2, 65) = 10.89, P < 0.0001
	(2R,6R)-HNK	Forepaw	0.036 ± 0.021	0.034 ± 0.016	0.031 ± 0.018	n.s.
		Hindpaw	0.050 ± 0.017	0.048 ± 0.023	0.039 ± .016	n.s.
Propel Duration (seconds)	Ketamine	Forepaw	0.177 ± 0.040	0.175 ± 0.046	0.142 ± 0.048	F(2, 65) = 4.240, P = 0.0186
		Hindpaw	0.250 ± 0.037	0.259 ± 0.051	0.224 ± 0.052	F(2, 65) = 3.235, P = 0.0458
	(2R,6R)-HNK	Forepaw	0.147 ± 0.030	0.144 ± 0.042	0.151 ± 0.025	n.s.
		Hindpaw	0.250 ± 0.052	0.254 ± 0.050	0.253 ± 0.051	n.s.
Brake Duration (seconds)	Ketamine	Forepaw	0.105 ± 0.029	0.127 ± 0.031	0.132 ± 0.038	F(2, 65) = 4.577, P = 0.0138
		Hindpaw	0.053 ± 0.024	0.076 ± 0.030	0.077 ± 0.028	F(2, 65) = 5.602, P = 0.0057
	(2R,6R)-HNK	Forepaw	0.130 ± 0.033	0.127 ± 0.026	0.120 ± 0.040	n.s.
		Hindpaw	0.061 ± 0.022	0.067 ± 0.029	0.065 ± 0.022	n.s.





**Table 1.** Gait analysis following the administration of ketamine and (2R,6R)-HNK. Computer analysis of gait form was performed 10 minutes following ketamine or (2R,6R)-HNK injection and assessed a variety of motor parameters using the DigiGait™ apparatus. The data shown are group means ± SD. Two separate cohorts, one for each medication, testing two doses against saline control were analyzed using a one-way ANOVA. N = 11-12 for the ketamine cohort and N = 10 for the (2R,6R)-HNK cohort.





**Figure 1**





**Figure 2**







Figure 3



A



B





Figure 4

## Antinociceptive and analgesic effects of (2R,6R)-hydroxynorketamine

Jonathan G. Yost, Hildegard A. Wulf, Caroline A. Browne, Irwin Lucki



**Supplementary Figure.** Data from Figures 1 & 2 displayed as percentage of maximum possible effect (%MPE), calculated according to the following equation:  $\%MPE = [(latency - baseline\ latency) / (cut\ off\ time - baseline\ latency)] \times 100$ . **Panel A:** Ketamine antinociception as %MPE. **Panel B:** (2R,6R)-HNK and (2S,6S)-HNK antinociception as %MPE. (2R,6R)-HNK antinociception in male mice (**Panel C**) compared to that of female mice (**Panel D**) expressed as %MPE. Results of the two-way ANOVA for panels A & B are as follows: Treatment –  $F(4, 90) =$

4.606,  $P = 0.0020$ . Time –  $F(3.6, 321.9) = 8.378$ ,  $P < 0.0001$ . Time x Treatment –  $F(16, 360) = 10.96$ ,  $P < 0.0001$ . Results of the two-way ANOVA for male mice are as follows: Treatment –  $F(1, 58) = 3.121$ ,  $P = 0.0825$ . Time –  $F(2.9, 168.3) = 4.779$ ,  $P = 0.0035$ . Time x Treatment –  $F(3, 174) = 4.499$ ,  $P = 0.0046$ . Results of the two-way ANOVA for female mice are as follows: Treatment –  $F(1, 70) = 8.886$ ,  $P = 0.0039$ . Time –  $F(2.7, 188.4) = 13.07$ ,  $P < 0.0001$ . Time x Treatment –  $F(3, 210) = 3.381$ ,  $P = 0.0192$ .